{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T19:45:13Z","timestamp":1767642313383,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11845-025-04113-0","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T02:58:51Z","timestamp":1759287531000},"page":"2183-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-820X","authenticated-orcid":false,"given":"Stephanie","family":"Bowe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitriona","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"2","key":"4113_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","volume":"89","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Lebwohl M, Langley RG et al (2023) Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 89(2):274\u2013282","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4113_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB (2014) Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 28(3):333\u2013337","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4113_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf198","author":"S Bowe","year":"2025","unstructured":"Bowe S, Murphy M, Bourke J, Ryan C (2025) Prescribing practices among psoriasis experts for patients with concomitant malignancy: a survey of International Psoriasis Council members. Clin Exp Dermatol. https:\/\/doi.org\/10.1093\/ced\/llaf198","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"4113_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.15665","volume":"177","author":"CH Smith","year":"2017","unstructured":"Smith CH, Jabbar-Lopez ZK, Yiu ZZ and others (2017) British association of dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 177(3):628\u2013636","journal-title":"Br J Dermatol"},{"issue":"4","key":"4113_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH and others (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4):1029\u20131072","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4113_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI and others (2020) Euroguiderm guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 34(11):2461\u20132498","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4113_CR7","doi-asserted-by":"publisher","first-page":"fl939","DOI":"10.1136\/bmj.f1939","volume":"346","author":"P Raaschou","year":"2013","unstructured":"Raaschou P, Simard JF, Holmqvist M et al (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 346:fl939","journal-title":"BMJ."},{"issue":"4","key":"4113_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16715","volume":"179","author":"I Garcia-Doval","year":"2018","unstructured":"Garcia-Doval I, Descalzo MA, Mason KJ and others (2018) Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. Br J Dermatol 179(4):863\u2013871","journal-title":"Br J Dermatol"},{"issue":"12","key":"4113_CR9","first-page":"1441","volume":"13","author":"AB Gottlieb","year":"2014","unstructured":"Gottlieb AB, Kalb RE, Langley RG and others (2014) Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 13(12):1441\u20131448","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"4113_CR10","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1111\/jdv.17230","volume":"35","author":"KJ Mason","year":"2021","unstructured":"Mason KJ, Burden AD, Barker JNWN and others (2021) Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. J Eur Acad Dermatol Venereol 35(8):e498-501","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"4113_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13555-021-00637-2","volume":"12","author":"JA Walsh","year":"2022","unstructured":"Walsh JA, CallisDuffin K, Van Voorhees AS and others (2022) Demographics, disease characteristics, and patient-reported outcomes among patients with psoriasis who initiated Guselkumab in CorEvitas\u2019 psoriasis registry. Dermatol Ther (Heidelb) 12(1):97\u2013119","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"4113_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/jdv.15448","volume":"33","author":"H Dickel","year":"2019","unstructured":"Dickel H, Bruckner T, H\u00f6xtermann S et al (2019) Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis. J Eur Acad Dermatol Venereol 33(5):893\u2013905","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"4113_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","volume":"149","author":"JJ Hoefnagel","year":"2003","unstructured":"Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN (2003) Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149(2):363\u2013369","journal-title":"Br J Dermatol"},{"issue":"6","key":"4113_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","volume":"60","author":"RV Patel","year":"2009","unstructured":"Patel RV, Clark LN, Lebwohl M, Weinberg JM (2009) Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 60(6):1001\u20131017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4113_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/bjd.15830","volume":"178","author":"E Peleva","year":"2018","unstructured":"Peleva E, Exton LS, Kelley K et al (2018) Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 178(1):103\u2013113","journal-title":"Br J Dermatol"},{"issue":"5","key":"4113_CR16","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/S2665-9913(24)00379-5","volume":"7","author":"JI Ruiz","year":"2025","unstructured":"Ruiz JI, Lei X, Giordano SH and others (2025) Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study. Lancet Rheumatol 7(5):e333\u2013e342","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"4113_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/sj.bjc.6605889","volume":"103","author":"JMG Larkin","year":"2010","unstructured":"Larkin JMG, Ferguson TR, Pickering LM and others (2010) A phase I\/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 103(8):1149\u20131153","journal-title":"Br J Cancer"},{"issue":"1","key":"4113_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/bjd.15830","volume":"178","author":"E Peleva","year":"2018","unstructured":"Peleva E, Exton LS, Kelley K et al (2018) Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 178(1):103\u2013113","journal-title":"Br J Dermatol"},{"issue":"13","key":"4113_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133713","volume":"13","author":"B Stephan","year":"2024","unstructured":"Stephan B, Rustenbach SJ, Ben-Anaya N and others (2024) Basic susceptibility of patients with psoriasis under systemic therapy for respiratory infections: data from the German Psoriasis Registry PsoBest. J Clin Med 13(13):3713. https:\/\/doi.org\/10.3390\/jcm13133713","journal-title":"J Clin Med"},{"issue":"12","key":"4113_CR20","first-page":"1441","volume":"13","author":"AB Gottlieb","year":"2014","unstructured":"Gottlieb AB, Kalb RE, Langley RG and others (2014) Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 13(12):1441\u20131448","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"4113_CR21","first-page":"1441","volume":"13","author":"AB Gottlieb","year":"2014","unstructured":"Gottlieb AB, Kalb RE, Langley RG and others (2014) Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 13(12):1441\u20131448","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"4113_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/cer-2020-0113","volume":"10","author":"JJ Wu","year":"2021","unstructured":"Wu JJ, Harrison RW, Zhu B and others (2021) Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry. J Comp Eff Res 10(2):157\u2013167","journal-title":"J Comp Eff Res"},{"issue":"2","key":"4113_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jdv.19520","volume":"38","author":"K Kridin","year":"2024","unstructured":"Kridin K, Abdelghaffar M, Mruwat N et al (2024) Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-insights from an international population-based study. J Eur Acad Dermatol Venereol 38(2):315\u2013324","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"4113_CR24","doi-asserted-by":"publisher","first-page":"T702","DOI":"10.1016\/j.ad.2024.05.011","volume":"115","author":"L Puig","year":"2024","unstructured":"Puig L, Notario J, L\u00f3pez-Ferrer A and others (2024) [Translated article] Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis. Actas Dermosifiliogr 115(7):T702\u2013T711","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"4113_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","volume":"77","author":"D Fiorentino","year":"2017","unstructured":"Fiorentino D, Ho V, Lebwohl MG and others (2017) Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol 77(5):845\u201354.e5","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"4113_CR26","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"PH Schafer","year":"2014","unstructured":"Schafer PH, Parton A, Capone L and others (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 26(9):2016\u20132029","journal-title":"Cell Signal"},{"issue":"5","key":"4113_CR27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","volume":"24","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Hatemi G, Paris M and others (2023) Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and beh\u00e7et\u2019s syndrome. Am J Clin Dermatol 24(5):809\u2013820","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"4113_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3899\/jrheum.171457","volume":"46","author":"DA Pappas","year":"2019","unstructured":"Pappas DA, Rebello S, Liu M and others (2019) Therapy with biologic agents after diagnosis of solid malignancies: results from the Corrona registry. J Rheumatol 46(11):1438\u20131444","journal-title":"J Rheumatol"},{"issue":"2","key":"4113_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI and others (2021) Euroguiderm guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 35(2):281\u2013317","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"4113_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T and others (2020) British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol 183(4):628\u2013637","journal-title":"Br J Dermatol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04113-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-04113-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04113-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:31:25Z","timestamp":1767630685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-04113-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4113"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-04113-0","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reviewed and approved by Clinical Research Ethics Committee (CREC).CREC Review Reference Number: ECM 4 (q) 05\/12\/2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Dr. Stephanie Bowe, Prof. Michelle Murphy and Dr. John Bourke have no conflicts of interest. Prof. Ryan has received honoraria for serving on advisory boards, as a speaker, or as a consultant from AbbVie, Allergan, Bristol Myers Squibb, Janssen, Leo, Lilly, Novartis, Pfizer, Regeneron-Sanofi and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}